Evidence map›Paper›PMID 41574641›Full record

Trial reportInternational wound journal2026

A Prospective Randomised Clinical Study Comparing Polygalacturonic and Caprylic Acid Ointment to Medical-Grade Honey in the Management of Chronic Wounds.

Hiba Dagher, Ray Y Hachem, Christopher Hakim, Rola Husni, Diya' S Hammoudeh, Mira Bou Karroum, Nelson Hamerschlak, Fernanda Ferraz Assir, Janane Nasr, Joel Rosenblatt and 9 more

Abstract readRandomized Controlled TrialComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International wound journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Hiba DagherDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ray Y HachemDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christopher HakimDivision of Plastic Surgery in the Department of Surgery, The American University of Beirut Medical Center, Beirut, Lebanon.
Rola HusniDivision of Infectious Diseases in the Department of Internal Medicine, Lebanese American University School of Medicine and Medical Center-Rizk Hospital, Beirut, Lebanon.
Diya' S HammoudehDivision of Plastic Surgery in the Department of Surgery, The American University of Beirut Medical Center, Beirut, Lebanon.
Mira Bou KarroumDivision of Infectious Diseases in the Department of Internal Medicine, Lebanese American University School of Medicine and Medical Center-Rizk Hospital, Beirut, Lebanon.
Nelson HamerschlakDepartment of Oncology and Hematology, Albert Einstein Israelite Hospital, São Paulo, Brazil.
Fernanda Ferraz AssirAlbert Einstein Israelite Hospital, São Paulo, Brazil.
Janane NasrDivision of Infectious Diseases in the Department of Internal Medicine, Lebanese American University School of Medicine and Medical Center-Rizk Hospital, Beirut, Lebanon.
Joel RosenblattDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-4130-7186
Ying JiangDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Saliba WehbeDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rony M ZeennyDepartment of Pharmacy, The American University of Beirut Medical Center, Beirut, Lebanon.
Y-Lan TruongDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Anne-Marie ChaftariDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Odette GhanemDivision of Plastic Surgery in the Department of Surgery, The American University of Beirut Medical Center, Beirut, Lebanon.
Amir IbrahimDivision of Plastic Surgery in the Department of Surgery, The American University of Beirut Medical Center, Beirut, Lebanon.
Abdul Rahman BizriDepartment of Infectious Diseases, The American University of Beirut Medical Center, Beirut, Lebanon.
Issam I RaadDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672The University of Texas MD Anderson Cancer Center Sister Institution Fund P30CA016672
6 · The paper itself

Abstract

The aim in this human trial is to compare the efficacy and safety of polygalacturonic-caprylic acid (PG-CAP) ointment to MediHoney in chronic wounds at three international medical centres. In this prospective open-label study, patients with chronic full-thickness wounds were randomised to daily treatment with PG-CAP ointment or MediHoney. Assessments were obtained weekly for 6 weeks. The validated Pressure Ulcer Scale for Healing (PUSH) score was used to track healing. Efficacies were compared using the Wilcoxon rank-sum test for continuous variables and chi-square or Fisher's exact test for categorical variables. Twenty-six patients with chronic wounds were included. Baseline characteristics were comparable between the groups; however, the history of diabetes mellitus was higher in the PG-CAP group (p = 0.011). All 13 PG-CAP patients showed improvement (100%), compared to only 69% of the 13 MediHoney patients (p = 0.023). Half of the failures in the MediHoney arm were associated with death (15%). No failures, adverse events or deaths occurred in the PG-CAP arm. PG-CAP wound ointment is a novel combination of two plant-based compounds that pose minimal risk of promoting antimicrobial resistance, was highly effective for eradicating wound-pathogen biofilms in vitro and promoted chronic wound healing in vivo with minimal inflammatory reactions. Our findings support PG-CAP as safe, noninferior and possibly more effective than MediHoney in healing chronic contaminated wounds.

Indexed as

HoneyPectinsPressure UlcerWound HealingWounds and InjuriesAdultAgedAged, 80 and overChronic DiseaseFemaleHumansMaleMiddle AgedOintmentsProspective StudiesTreatment OutcomeOintmentsPectinsantimicrobial ointmentcaprylic acidinfected woundsMediHoneypolygalacturonic acidwound healing

Identifiers

PMID41574641
PMCPMC12828265

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.